Based on this, we postulated that kinases that regulate sequential steps in DDR mechanisms are potential drug targets that can sensitize tumor cells to chemotherapy and IR because of an impaired DDR, which will result in a loss of tumor cell viability, particularly if these tumors have mutations in ATM, BRCA1 or TP53 genes. Here, BRCA1 is linked to neoplasm.